Moreover in hepatocellular carcinoma (HCC), cholangiocarcinoma (CGC), and Chronic myeloid leukemia (CML) a lesser accumulation of anticancer drugs (like imatinib) seems to be mediated by a decrease in OATP1B1, OATP1B3, and OATP1A2 expression or their function [317, 320, 321]. Here, SLCO1B1 is linked to hepatocellular carcinoma.